Coulter Partners provides leadership consultancy to Life Sciences, Health and Technology innovation businesses globally. We build teams that change the world and create a better future. Over 20 years we have delivered on 1000s of assignments across the USA, Canada, UK/Europe, and APAC, advising companies and investors on how to shape and hire their boards and leadership teams. We strongly impact value and growth. Our 110 experts operate uniquely as one global team. With our track record, AI, bespoke systems and wealth of data, we fuel the ability of investors, boards and executive teams to deliver value from innovation.
The Coulter Partners team is made up of 110 experts, working in 40 countries, holding 250,000 conversations with industry leaders each year. Together we channel data and learning to the benefit of our clients. We are a diverse group of experts with backgrounds ranging from science and technology, to the arts, finance, and more. Our reward system is designed to drive one-team behaviors and we work together seamlessly to combine industry experience and global insight with our passion for progress. Our team understands and is up to date with the challenges you face and the opportunities your business can maximize. This means we can find and develop exceptional individuals to drive you forward.
Our network is carefully curated and gives us access to leaders who can guide science, technology and innovation-driven companies through all stages of growth and evolution. Our executive search is an end-to-end process, underpinned by rigorous data and analytics from our dedicated Business Intelligence function and CP:Net™, our proprietary AI-driven candidate and company database. Our Board Advisory brings over two decades’ experience in building, advising and evolving boards for private and public companies. We understand what value a board can bring and how to evaluate its suitability for the stage of the business and the 3–5-year plan. We also provide leadership advisory at every step of the way. We have a network of mentors and advisors that bring the next level of insight to your organization, to build teams that change the world.
Life sciences search specialist Coulter Partners has placed Francisco Salva as president and CEO of Azitra Inc. in Branford, CT. He replaces Rick Andrews who is retiring. Client partner Chris Palatucci led the assignment. “We are excited to bring in Francisco’s remarkable experience and leadership,” said Travis Whitfill, co-founder, executive director of advanced technology and chair, scientific
Life sciences search specialist Coulter Partners has placed Walter Miller as chief finance officer and Charles Woler as non-executive director of Optimapharm. Directors Mark Sharp and Irene Montgomery led the assignment. “It has been a privilege to partner with Optimapharm on two more key search assignments, following our collaboration to bring Andrew Copestake on board as CEO
Life sciences search specialist Coulter Partners has placed Brian O’Callaghan as chief executive officer of ObsEva, a clinical-stage biopharmaceutical company developing and commercializing novel therapies for women’s reproductive health. Client partner Nona Footz led the assignment. Mr. O’Callaghan succeeds Ernest Loumaye, who co-founded the firm in 2012. As ObsEva evolves from a development company toward
Life sciences search specialist Coulter Partners has formed a partnership with BioInnovation Institute (BII), the international incubator in Denmark for research-based innovation and entrepreneurship. The firm has been engaged to provide support for BII across three workstreams: providing assessment, coaching and development for the CEOs of start-up businesses in BII’s portfolio under the Creation House
(Aug. 20, 2020) Coulter Partners was very pleased to partner recently with Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, to secure the appointment of Oliver Gödje, MD, PhD, as Chief Medical Officer. Dr Gödje replaces Gijs Klarenbeek, MD, who remains
(July 28, 2020) Coulter Partners was delighted to partner recently with Optimapharm to secure the appointment of Dr. Andrew Copestake as Chief Executive Officer. Andrew joins Optimapharm’s executive management team following several months advising the company’s Board of Directors. Optimapharm is a contract research organization managing clinical trials on behalf of leading biotech, pharma and
(June 20, 2020) Coulter Partners was delighted to partner recently with Pharming Group N.V. (Euronext Amsterdam: PHARM), to secure the nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Until that moment, Barbara
LONDON, UK., January 2020 – Coulter Partners was delighted to partner recently with Stilla Technologies, provider of pioneering digital PCR (dPCR) solutions for high-precision genetic analysis, to secure the appointment of Khaled Bahi as Chief Financial Officer. His appointment comes at a time of rapid growth for the company, with the recent opening of a U.S.
LONDON, U.K., April 2019 – Coulter Partners has partnered again with Pivot Bio, an agriculture technology company based in Silicon Valley, to secure the appointment of Christa Peren as Vice President of Finance. Christa Peren joined Pivot Bio as VP-Finance in February 2019, bringing more than 25 years of business finance experience to the role.
Blogs
Top hires for VC & PE portfolio companies Q1-2024
D, E & I: VIEWS FROM LEADERSHIP SERIES – Lene Gerlach, Founder and Chair of Women in Life Science Denmark (WiLD), and Partner at Eir Ventures
D, E & I: VIEWS FROM LEADERSHIP SERIES – Yael Gruenbaum-Cohen, Partner at aMoon and Founder of WE@HealthTech
Top hires for VC & PE portfolio companies Q4-2023
Top global hires for large-cap, mid-cap and public companies H2-2023
Top hires for VC & PE portfolio companies Q3-2023
Top hires for VC & PE portfolio companies Q2-2023
Top global hires for large-cap, mid-cap and public companies H1-2023
Top hires for VC & PE portfolio companies Q1-2023
D, E & I: Views From Leadership Series – Charlotte Valeur, Founder of Institute Of Neurodiversity, ION
Top hires for VC & PE portfolio companies Q4-2022
Top global hires for large-cap, mid-cap and public companies H2-2022
Diversity, Equity, & Inclusion: Views From Leadership Series- Quita Highsmith, Vice President and Chief Diversity Officer at Genentech
Diversity, Equity & Inclusion: Views from Leadership-Tomoko Adachi
Diversity, Equity & Inclusion: Views from Leadership-Corinne Le Goff